|
|
免疫检查点抑制剂联合抗血管生成药物治疗肺肉瘤样癌：1例病例报告及文献综述
|
Abstract:
肺肉瘤样癌(Pulmonary sarcomatoid carcinoma, PSC)是一种罕见的非小细胞肺癌(non-small cell lung cancer, NSCLC)，具有分化差、进展迅速、易远处转移等特点，对常规抗肿瘤治疗的应答率低，预后差。最近的研究发现，PSC通常具有潜在的可靶向的基因组改变、高肿瘤突变负荷、高水平的免疫细胞浸润和更高的PD-L1表达，这为我们提供了PSC患者可能受益于免疫治疗的前景。由于肿瘤的生长和转移依赖于血管生成，抗血管生成治疗在癌症治疗中发挥着越来越重要的作用。目前，已有研究证实抗血管生成药物联合免疫检查点抑制剂(Immune checkpoint inhibitors, ICIs)治疗晚期NSCLC的有效性和安全性，但未发现PSC的获益。在这里，我们报道的一例晚期PSC患者使用ICI联合抗血管生成治疗的成功病例显示了显著的疗效，这为PSC患者提供了一个有前途的选择。
Pulmonary sarcomatoid carcinoma (PSC), characterized by poor differentiation, aggressive progres-sion, and easy distant metastasis, is a rare type of non-small cell lung cancer (NSCLC), which shows a low response rate to conventional antitumor therapies and has a poor prognosis. Recent studies have found that PSC commonly harbors potential targetable genomic alterations, high tumor muta-tion burden, high level of immune-cell infiltration, and higher PD-L1 expression, which gives us the prospect that PSC patients may be able to benefit from immunotherapy. As tumor growth and me-tastasis depend on angiogenesis, antiangiogenesis therapy is playing an increasingly crucial role in cancer treatment. At present, some studies have confirmed the efficacy and safety of antiangiogenic drugs combined with Immune checkpoint inhibitors (ICIs) in the treatment of advanced NSCLC, but no benefit has been found in PSC. Here, the successful case of a patient with advanced PSC using ICI combined with antiangiogenic therapy we reported shows significant benefits, which provides a promising option for PSC patients.
| [1] | Lin, Y., Yang, H., Cai, Q., et al. (2016) Characteristics and Prognostic Analysis of 69 Patients with Pulmonary Sarco-matoid Carcinoma. American Journal of Clinical Oncology, 39, 215-222.
https://doi.org/10.1097/COC.0000000000000101 |
| [2] | Martin, L.W., Correa, A.M., Ordonez, N.G., et al. (2007) Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis. The Annals of Thoracic Surgery, 84, 973-980. https://doi.org/10.1016/j.athoracsur.2007.03.099 |
| [3] | Kim, S., Kim, M.-Y., Koh, J., et al. (2015) Programmed Death-1 Ligand 1 and 2 Are Highly Expressed in Pleomorphic Carcinomas of the Lung: Comparison of Sarcomatous and Carcinomatous Areas. European Journal of Cancer, 51, 2698-2707. https://doi.org/10.1016/j.ejca.2015.08.013 |
| [4] | Babacan, N.A., Pina, I.B., Signorelli, D., et al. (2020) Relationship between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clinical Lung Cancer, 21, e456-e463. https://doi.org/10.1016/j.cllc.2020.02.022 |
| [5] | Shukla, N.A., Yan, M.N. and Hanna, N. (2020) The Story of An-giogenesis Inhibitors in Non-Small-Cell Lung Cancer: The Past, Present, and Future. Clinical Lung Cancer, 21, 308-313. https://doi.org/10.1016/j.cllc.2020.02.024 |
| [6] | Travis, W.D., Brambilla, E., Nicholson, A.G., et al. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology, 10, 1243-1260. https://doi.org/10.1097/JTO.0000000000000630 |
| [7] | Ma, Y., Li, W., Li, Z., et al. (2022) Immunophenotyping of Pulmonary Sarcomatoid Carcinoma. Frontiers in Immunology, 13, Article 976739. https://doi.org/10.3389/fimmu.2022.976739 |
| [8] | Boland, J.M., Mansfield, A.S. and Roden, A.C. (2017) Pulmo-nary Sarcomatoid Carcinoma—A New Hope. Annals of Oncology, 28, 1417-1418. https://doi.org/10.1093/annonc/mdx276 |
| [9] | Zhou, F., Huang, Y., Cai, W., et al. (2021) The Genomic and Immu-nologic Profiles of Pure Pulmonary Sarcomatoid Carcinoma in Chinese Patients. Lung Cancer, 153, 66-72. https://doi.org/10.1016/j.lungcan.2021.01.006 |
| [10] | Jiao, Y., Liu, M., Luo, N., Guo, H. and Li, J. (2021) Successful Treatment of Advanced Pulmonary Sarcomatoid Carcinoma with the PD-1 Inhibitor Toripalimab: A Case Report. Oral Oncology, 112, Article ID: 104992.
https://doi.org/10.1016/j.oraloncology.2020.104992 |
| [11] | Taniguchi, H., Takemoto, S., Ozasa, M., et al. (2021) Remarkable Response to Pembrolizumab with Platinum-Doublet in Pd-L1-Low Pulmonary Sarcomatoid Carcinoma: A Case Report. Thoracic Cancer, 12, 1126-1130.
https://doi.org/10.1111/1759-7714.13890 |
| [12] | Velcheti, V., Rimm, D.L. and Schalper, K.A. (2013) Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal of Thoracic Oncology, 8, 803-805. https://doi.org/10.1097/JTO.0b013e318292be18 |
| [13] | Li, X., He, Y., Zhu, J., et al. (2018) Apatinib-Based Targeted Therapy against Pulmonary Sarcomatoid Carcinoma: A Case Report and Literature Review. Oncotarget, 9, 33734-33738. https://doi.org/10.18632/oncotarget.25989 |
| [14] | Kong, F.-W., Wang, W.-M., Liu, L., et al. (2020) First-Line Albumin-Bound Paclitaxel/Carboplatin plus Apatinib in Advanced Pulmonary Sarcomatoid Carcinoma: A Case Series and Review of the Literature. Medicine, 99, e20667.
https://doi.org/10.1097/MD.0000000000020667 |
| [15] | Zhao, S., Ren, S., Jiang, T., et al. (2019) Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 7, 630-643.
https://doi.org/10.1158/2326-6066.CIR-17-0640 |
| [16] | Zhou, C., Wang, Y., Zhao, J., et al. (2021) Efficacy and Bi-omarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. Clinical Cancer Research, 27, 1296-1304. https://doi.org/10.1158/1078-0432.CCR-20-3136 |
